Anixa BiosciencesANIX
ANIX
About: Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Employees: 5
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $122K | Put options by funds: $71K
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
18% more capital invested
Capital invested by funds: $13.6M [Q4 2024] → $16M (+$2.48M) [Q1 2025]
2% more funds holding
Funds holding: 57 [Q4 2024] → 58 (+1) [Q1 2025]
0.74% less ownership
Funds ownership: 18.15% [Q4 2024] → 17.41% (-0.74%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
110%
upside
Avg. target
$9
169%
upside
High target
$10
199%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 199%upside $10 | Buy Maintained | 10 Jun 2025 |
HC Wainwright & Co. Yi Chen | 110%upside $7 | Buy Reiterated | 25 Mar 2025 |
Maxim Group Jason McCarthy | 199%upside $10 | Buy Initiated | 21 Mar 2025 |
Financial journalist opinion
Based on 8 articles about ANIX published over the past 30 days
Positive
Zacks Investment Research
5 days ago
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Neutral
PRNewsWire
5 days ago
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage
SAN JOSE, Calif. , June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends.
Neutral
PRNewsWire
6 days ago
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
SAN JOSE, Calif. , June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria.
Positive
Zacks Investment Research
1 week ago
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy
Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Negative
Zacks Investment Research
1 week ago
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Neutral
PRNewsWire
1 week ago
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview
SAN JOSE, Calif. , June 3, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed on NewsNation's "Elizabeth Vargas Reports" to discuss Anixa's breast cancer vaccine.
Neutral
PRNewsWire
1 week ago
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
SAN JOSE, Calif. , June 2, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast cancer vaccine.
Neutral
PRNewsWire
3 weeks ago
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones
SAN JOSE, Calif. , May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today released a letter to shareholders from Chairman and CEO Dr. Amit Kumar, detailing significant progress across its programs and outlining key milestones for the remainder of the year.
Neutral
PRNewsWire
1 month ago
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois.
Neutral
PRNewsWire
1 month ago
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th
SAN JOSE, Calif. , April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C.
Charts implemented using Lightweight Charts™